RECOMBINANT ZAIRE EBOLAVIRUS KIKWIT-95 ENVELOPE GLYCOPROTEIN MODIFIED VESICULAR STOMATITIS VIRUS for hemorrhagic fever, ebola

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 23 Aug 2016: Trial registered, NCT02876328
  2. 27 Mar 2017: Trial started, NCT02876328

The trials

NCT02876328: Partnership for Research on Ebola VACcinations

State
Completed
Phase
Phase 2
People
4,789 taking part
Started
27 Mar 2017
Primary completion
24 Dec 2019
Arms
rVSVΔG-ZEBOV-GP (rVSV) vaccine + placebo boost, rVSVΔG-ZEBOV-GP (rVSV) vaccine + rVSV boost
Results
Posted on the registry
  1. 23 Aug 2016: Trial registered
  2. 27 Mar 2017: Trial started
  3. 28 Sep 2022: Trial results posted
  4. 20 Dec 2023: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Also known as rVSV boost, rVSVΔG-ZEBOV-GP.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.